What is it about?
I explore the current legal situation in the EU. I propose alternative interpretations of the Oviedo Convention. I hold that germ line modification is allowed in the EU and the Council of Europe framework if performed for research purposes and even for clinical purposes under some conditions.
Featured Image
Why is it important?
It provides researchers with an innovative point of view on a very hot issue
Perspectives
I think that researchers willing to work on germ line modifications via CRISPR-Cas should read this paper.
iñ DE MIGUEL BERIAIN
UNIVERSITY OF THE BASQUE COUNTRY
Read the Original
This page is a summary of: Legal issues regarding gene editing at the beginning of life: an EU perspective, Regenerative Medicine, September 2017, Future Medicine,
DOI: 10.2217/rme-2017-0033.
You can read the full text:
Contributors
The following have contributed to this page
